Background: Risk for posttraumatic stress disorder (PTSD) is thought to be mediated by gene × environment (G × E) interactions that affect core cognitive processes such as fear learning. The catechol-O-methyltransferase (COMT) val158met polymorphism has been associated with risk for PTSD and impaired fear inhibition. We used a large, relatively homogenous population to (1) replicate previous findings of poor fear inhibition in COMT Met/Met carriers with PTSD; (2) determine if COMT association with fear inhibition is moderated by childhood trauma (CT), an environmental risk factor for PTSD; and (3) determine if COMT is associated with altered fear processes after recent exposure to combat trauma.
INTRODUCTION
Posttraumatic stress disorder (PTSD) affects 7-8% of the American population and up to 20% of military veterans (Pace & Heim, 2011) .
The risk of developing PTSD, which is characterized by intrusive reexperiencing of a traumatic event, avoidance of trauma-related stimuli and hyperarousal, is close to 40% in individuals who endorsed a sufficiently high number of traumatic events (Kolassa, Kolassa, Ertl, Papassotiropoulos, & De Quervain, 2010; Neuner et al., 2004) . In the USA, 61% of men and 51% of women endorsed at least one trauma in their lifetime (Kessler, Ruscio, Shear, & Wittchen, 2010; Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995) . Because only a fraction of those that experience trauma go on to develop chronic PTSD symptoms, understanding the biological risk factors that contribute to PTSD is important and may lead to the development of novel prophylactic and treatment targets.
In humans, a commonly carried single nucleotide polymorphism (SNP) in the coding sequence for COMT, with valine (Val) being substituted by methionine (Met) at amino acid residue 158, results in a 40% reduction in COMT enzymatic activity in Met/Met carriers, leading to increased catecholamine tone in Met/Met carriers, particularly in the cortex (Chen et al., 2004) . This SNP (rs4680) has been associated with the risk for several neuropsychiatric disorders, although these associations are controversial and inconsistent (Almli, Fani, Smith, & Ressler, 2013; Clark et al., 2013; Goenjian et al., 2014) . Some human studies reported that Met/Met carriers are at higher risk of developing PTSD by exhibiting impaired affective function, reduced fear extinction, and exaggerated potentiated startle reflex and anxiety (Enoch, Xu, Ferro, Harris, & Goldman, 2003; Lonsdorf et al., 2009; Montag et al., 2008; Zubieta et al., 2003) . Nevertheless, the relationship between COMT val158met polymorphism and PTSD remains inconclusive (Li et al., 2016) , suggesting the importance of gene × environment interactions in the development of PTSD. Although several studies have shown COMT val158met polymorphism × trauma interactions on risk for PTSD, it remains unclear how the SNP interacts with other PTSD risk factors such as early life stress or recent trauma (Boscarino, Erlich, Hoffman, & Zhang, 2012; Kolassa et al., 2010; Valente et al., 2011) .
PTSD is associated with increased fear responding, reduced safety signal learning, and poor fear extinction (Acheson, Geyer, et al., 2015; . Although previous studies have indicated that homozygous Met carriers similarly exhibit increased conditioned fear, reduced safety signal learning, and/or impaired fear extinction (Lonsdorf et al., 2009; Norrholm et al., 2013; Wendt et al., 2015) , the results are inconsistent as to whether these alterations are found in healthy subjects or in subjects with current PTSD symptoms only.
Childhood trauma is a strong predictor of PTSD in adulthood, and is well known to interact with genes to modulate PTSD risk (Mehta & Binder, 2012) . However, it is not clear how early life stress may modify COMT associations with fear learning processes, or if these processes are altered by recent trauma exposure. In the present study, we used a large, relatively homogenous population to (1) replicate previous findings of altered fear processes in COMT Met/Met carriers with and without PTSD; (2) determine if COMT associations with fear learning and inhibition are moderated by childhood trauma, a strong environmental risk factor for PTSD; and (3) determine if COMT is associated with altered fear processing after exposure to recent combat trauma.
METHODS

Study design and participants
The second phase of the Marine Resiliency study (MRS-II; Baker et al., 2012 ) involved a prospective longitudinal study of nearly 1,200 US Marines and Navy Corpsmen that were deployed to Afghanistan. The US Marines were from infantry battalions tested between October 2011 and October 2013, at bases in Southern California. Participants of European-American ancestry were assessed prior to (n = 714) and approximately 4-6 months after deployment to Afghanistan (n = 452) (see below for exclusion details). The study, for which all participants provided written informed consent, was approved by the institutional review boards of the University of California San Diego, Veterans Affairs San Diego Research Service, and Naval Health Research Center. Only males were included in the study because infantry battalions did not include females at the time of assessment.
Genotyping
COMT val158met SNP (rs4680) was genotyped as previously described . Briefly, blood samples were collected at the first visit and blood leukocytes were isolated. Genomic DNA was prepared from blood leukocytes at the Biomedical Genomics Microarray (BioGeM) Core facility (University of California San Diego, La Jolla, CA, USA) using the automated AutoGenFlex Star System, quantified with the Nanodrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Genotyping was performed by RUCDR Infinite Biologics (Piscataway, NJ, USA) with the human OmniExpress Exome array (Illumina Inc., San Diego, CA, USA). The assay call and reproducibility rates were >99%. SNPs for control samples (identified as those with no PTSD diagnosis) respected the Hardy-Weinberg Equilibrium (P < 5 × 10 −8 ). To control for race/ethnicity, we used ancestry identification using genetic markers as previously described (Nievergelt et al., 2013) to identify four possible ancestry categories:
African-American, Hispanic/Native American, European-American, and East Asian/other. All ancestries other than European-American were excluded to reduce population stratification. Within EuropeanAmericans, a principal component analysis (PCA) , implemented in EIGENSTRAT (Price et al., 2006) , was performed to control for additional genetic background heterogeneity.
PCAs were then used as covariates in all statistical models.
Childhood trauma questionnaire
Before deployment, participants completed a modified 34-item (25-170 range) Childhood Trauma Questionnaire (CTQ; Bernstein et al., 1994) to assess traumatic experiences (emotional, physical and sexual abuse, and emotional and physical neglect) during childhood. Presence of childhood trauma was determined based on cutoff scores as previously described (Agorastos et al., 2014) : emotional abuse: ≥13; physical abuse: ≥10; sexual abuse: ≥8; emotional neglect ≥15; physical neglect: ≥10. It has been shown that the risk for PTSD and depression symptoms were similar for both single and multiple childhood traumatic event types (Agorastos et al., 2014) . Therefore, we divided the childhood traumatic experiences in two categories: 0 (no childhood trauma) or 1 (at least one type of childhood trauma).
Combat experiences and stress
After deployment, combat trauma and stress during deployment were measured using the Deployment Risk and Resilience Inventory-2 (DRRI-2), with a high criterion validity and internal consistency (0.92) (Vogt et al., 2013) . From the questionnaire, a total Combat Experience Score (CES) was calculated that encompassed all the traumatic and stressful events during deployment. To determine the role of trauma exposure (CES, 0-56 possible score), we used a validated approach (Collings, Valjee, & Penning, 2013; DeSantis et al., 2011) : a median was calculated and the CES was divided in two groups: low (CES score ≤12) and high (CES score >12).
Assessment of psychiatric symptoms
As previously described (Baker et al., 2012; Glenn et al., 2016) , the Clinician-Administered PTSD Scale (CAPS), an interview designed to assess DSM-IV PTSD symptoms, was administered (Blake et al., 1995; Smith, Redd, DuHamel, Vickberg, & Ricketts, 1999; Weathers, Keane, & Davidson, 2001) . Four CAPS subscales were assessed based on symptoms: re-experiencing (B1-5); avoidance (C1-2); numbing (C4-6); and hyperarousal (D1-5). PTSD symptom severity was measured by the CAPS total score (0-136 range). PTSD diagnosis was defined based on modified "subthreshold" guidelines, specifically at least one criterion A event, one cluster B symptom, and either three cluster C or two cluster D symptoms (Blanchard et al., 1996) . Depression symptoms were assessed via self-report using the Beck Depression Inventory (BDI-II), which scores depressive symptoms as moderate to severe (>19) within the past 2 weeks (Beck, Steer, Ball, & Ranieri, 1996) .
Fear conditioning protocol
Fear conditioning was performed as previously described (Acheson, Eyler, Resovsky, Tsan, & Risbrough, 2015; Orcutt et al., 2016) . Briefly, a SR-HLAB Electromyography (EMG) system (San Diego Instruments, San Diego, CA, USA) was used to deliver startle pulses (108 dB, 40 ms). The air puff (250 psi) was delivered through a plastic tube The fear conditioning task was divided in two sessions: acquisition and extinction phases. Before the acquisition phase, each participant was instructed that one of two colored symbols presented was associated with an air puff. For stabilization of startle responding, each phase began with six startle pulses without stimuli. During the acquisition phase, eight conditioned stimuli (CS+; danger signal; either a blue or yellow circle or square) were presented for 6 s followed by an air puff in 75% contingency (previously measured and described; Acheson, Geyer, et al., 2015) and eight nonreinforced stimuli (CS−; safety signal; either a blue or yellow circle or square) were never paired with an air puff, and eight startle stimuli were presented in the absence of any stimuli (noise-alone trial). The noise-alone trials were used as an index of baseline startle across the phase. The startle pulses were presented 4 s after the onset of CS+ or CS− signal, and the stimuli (blue or yellow circles or squares) paired with the CS+ and CS− signals were randomly assigned across subjects. After the acquisition phase, participants rested for 5 min and were then told to remember the associations they have learned before starting the extinction phase. During the extinction phase, each stimulus (CS+, CS− and noise-alone) was presented 16 times, but no air puff was presented. Fear extinction learning in this task is relatively similar after both short (less than 10 min) or long delays (72 hr) after fear acquisition learning (Norrholm et al., 2008) .
F I G U R E 1
Chart indicating the number of participants recruited and excluded from the final analysis. a Technical difficulties included poor signal-to-noise or excessive artifact during testing; b Technical difficulties were due to high average noise.
Statistical analysis
A total of 1,134 US Marines were assessed at predeployment. Only participants of European-American ancestry (EA; n = 714) were included in the study due to potential population stratification (Met allele is less frequent in African-American, Hispanic, and Asian populations) (DeMille et al., 2002; Palmatier, Kang, & Kidd, 1999) . Data on seven participants were excluded from analysis due to technical difficulties during testing that resulted in low signal/noise ratio that precluded accurate signal measurement. Of the 714 EA participants analyzed in the predeployment phase, 524 completed all the questionnaires and fear conditioning testing at postdeployment and two participants were excluded from the analysis due to technical difficulties.
Among the 522 participants from whom all the parameters were successfully obtained after deployment, 70 participants were excluded from the postdeployment analysis because they had been diagnosed with PTSD before deployment, which could have confounded interpretation of deployment effects on fear processing (Fig. 1) .
Fear conditioning data were analyzed as previously described, standard for this FPS protocol (Acheson, Geyer, et al., 2015) . Within each block, the noise-alone startle averages were subtracted from the CS+ and CS− averages to adjust for changes in baseline startle across the session. As in past studies using this task, to assess fear acquisition, we collapsed the last half of the trials in the acquisition phase (Acheson, Geyer, et al., 2015) . To assess fear extinction, we followed the statistical conventions described by our group and others for this task (Acheson, Geyer, et al., 2015; Norrholm et al., 2011) by collapsing each trial type into four equal blocks, the first block (early) consisting of the first four trials of the phase, the second block (mid 1) trials 5-8, the third block (mid 2) trials 9-12, and the last block (late) trials 13-16.
We first determined if our study replicated previous reports of Met/Met increases in FPS during acquisition and extinction in subjects with PTSD, using the predeployment data set. Repeated measures twoway (Genotype × PTSD diagnosis) analysis of variance (ANOVA), with block as within-subjects factor and childhood trauma (total CTQ score), lifetime trauma burden (Life Event Checklist, LEC; Gray, Litz, Hsu, & Lombardo, 2004) , CAPS score, and four ancestry PCAs as covariates, was used for each CS trial separately, followed by Sidak post hoc tests, as appropriate. We separated the CS trial types because of the difficulty in interpreting and powering analyses with more than three-way interactions and because previous studies suggest that CS− responses are strongly associated with COMT val158met genotype (Norrholm et al., 2013) . We next asked if childhood trauma moderates the relationship between COMT genotype and PTSD on FPS acquisition and extinction. Therefore, repeated measures three-way ANOVA (Genotype × PTSD diagnosis × childhood trauma), with block as withinsubjects factor, and LEC, CAPS score, and ancestry PCAs as covariates, was conducted, followed by Sidak post hoc tests. Finally, to investigate the effect of recent combat trauma exposure on FPS, repeated measures two-way ANOVA (Genotype × CES), with block as withinsubjects factor, and childhood trauma, LEC, CAPS score, and ancestry PCAs as covariates, was performed, followed by Sidak post hoc tests.
Interactions with block were followed by separate ANOVAs at each block.
RESULTS
Demographic and trauma history of participants
Demographic and descriptive information of participants in MRS-II have been described previously (Acheson, Geyer, et al., 2015; Minassian et al., 2015) . Predeployment demographic and trauma information are described for each COMT genotype (Table 1) . Following one-way ANOVA, no differences in age, months spent in military, childhood or lifetime trauma history (CTQ and LEC, respectively), or BDI-II score were found across COMT genotype groups before deployment (Table 1) , and chi-square test revealed no difference in marital status, education, or PTSD diagnosis (Table 1) 
Met/Met genotype is associated with increased fear-potentiated startle in individuals with PTSD and childhood trauma exposure
We first determined if our study replicated previous reports of Met/Met increases in FPS during acquisition and extinction in participants with PTSD when controlling for trauma burden and childhood trauma. In the acquisition phase, genotype was not associated with differences in FPS during either the CS+ or CS− (no main effects or interactions with PTSD group, Figure 2 ; for table of means ± SEMs, see Supplementary Table 1 ). PTSD participants exhibited increased FPS to the CS− (F 1,701 = 8.85; P < .01) regardless of genotype (Fig. 2b) . During extinction, main effects of block (F 3,701 = 10.83; P < .001 and F 3,701 = 11.07; P < .001) were observed on CS+ and CS− signal, respectively, but did not interact with other factors (Fig. 3a-f ; for table of means ± SEMs, see Supplementary Table 1 ). There were no significant associations of genotype or PTSD with CS+ responding (Fig. 3g) . Across the CS− trials, however, Met/Met carriers diagnosed with PTSD had increased FPS compared to Met/Met carriers without PTSD (Genotype: F 2,701 = 4.48, P < .05; Genotype × PTSD: F 2,701 = 3.21, P < .05, followed by post hoc test P < .05) (Fig. 3h) . These results replicate previous We next asked if childhood trauma moderates the relationship between COMT genotype and PTSD on FPS acquisition and extinction.
In the acquisition phase, three-way ANOVA (Genotype × PTSD diagnosis × Childhood trauma) showed no main effects of childhood trauma or interactions with the other factors during the CS+ or CS− trials (see above). During the extinction phase, all groups showed significant reductions in potentiation to both the CS+ and CS− trials (main effects of block: F 3,696 = 10.82; P < .001 and F 3,696 = 9.51; P < .001) (Fig. 4a-f ).
Whereas no genotype associations were observed with FPS during the CS+ trials (Fig. 4g) , a Genotype × PTSD diagnosis × Childhood trauma interaction was observed (F 2,696 = 3.50, P < .05; Genotype: F 2,696 = 3.80, P < .05; Genotype × PTSD: F 2,696 = 2.96, P = .05) on FPS across the CS− trials (Fig. 4h) . Post hoc comparisons indicated that high FPS during the safety signal in Met/Met carriers with PTSD was primarily found in participants that endorsed childhood trauma (P < 0.05, compared to Met/Met carriers not diagnosed with PTSD, but with at least one childhood trauma) (Fig. 4h) , whereas Met/Met carriers with PTSD but without childhood trauma were not different than carriers without PTSD.
Increased fear-potentiated startle in Met/Met carriers after deployment is moderated by combat trauma
We next investigated the effect of deployment-related combat trauma exposure on FPS after return from deployment. To assess combat trauma effects, we grouped subjects into high and low trauma exposure via a median split of combat experience scores (CES) assessed by the DRRI after deployment. To control for chronic PTSD, we excluded participants who were already diagnosed with PTSD at predeployment. In TA B L E 1 Demographic characteristics, trauma history and psychiatric symptoms scores across COMT genotype groups before deployment (Fig. 6a-c) . During the CS− signal, a main effect of block was found (F 3,439 = 5.73; P < .001), but no effect of either genotype or combat trauma was found on FPS ( Fig. 6d-f ).
COMT
DISCUSSION
The present study aimed to verify whether COMT val158met polymorphism moderated impaired fear processes observed in PTSD, if these associations were further moderated by childhood trauma, and if genotype was associated with recent trauma effects on learned fear (Boscarino et al., 2012; Kolassa et al., 2010; Valente et al., 2011) . To the best of our knowledge, the findings presented here are the first to report Gene × Environment risk factor interactions in disruption of fear inhibition, a behavioral characteristic linked to the fearrelated symptoms of PTSD (Acheson, Geyer, et al., 2015; Jovanovic et al., 2010) .
Marines with no history of PTSD symptoms before deployment, who carried the Met/Met genotype and endorsed high combat trauma showed modest increases in FPS to the CS+ during extinction compared to Met/Met carriers who experienced low trauma or were Val/Val carriers. These findings suggest that acute trauma exposure, and more importantly, current PTSD symptoms are necessary to observe COMT val158met associations with altered fear processes.
Two other studies have reported modulation of fear extinction by the COMT val158met polymorphism in healthy controls (Lonsdorf et al., 2009; Wendt et al., 2015) , but those studies did not control for lifetime trauma. In sum, our finding that COMT SNP-modulated response to severe combat trauma is in agreement with the Gene × Environment hypothesis of PTSD. Interestingly, impaired fear extinction has been specifically associated with PTSD, not depression or anxiety, in active-duty Marines (Acheson, Geyer, et al., 2015; Jovanovic et al., 2010) , suggesting that impaired fear conditioning before deployment might be a predictor of higher PTSD risk after combat. (Abraham, Neve, & Lattal, 2014; Quirk & Mueller, 2008) . Although COMT is mainly expressed in the PFC, the involvement of other brain regions, such as hippocampus, should not be excluded. The hippocampus modulates contextual fear learning through dopaminergic activity (Abraham et al., 2014; Phillips & LeDoux, 1992) . Interestingly, COMT val158met polymorphism has been associated with changes in hippocampal CA2/3 volumes, which is negatively correlated with trauma exposure in Met/Met (Rabl et al., 2014) . Decreased hippocampal volume has been reported in civilian trauma-related PTSD (Smith, 2005; Villarreal et al., 2002; Woon, Sood, & Hedges, 2010) and combat-related PTSD (Gurvits et al., 1996) , and has been shown to predict vulnerability to psychological trauma (Gilbertson et al., 2002) . Therefore, COMT val158met polymorphism could alter contextual fear inhibition through changes in hippocampal function. Additionally, COMT may affect fear inhibition via modulation of norepinephrine signaling (Chen et al., 2004; Mier, Kirsch, & Meyer-Lindenberg, 2010) . The COMT enzyme catabolizes norepinephrine (Tunbridge, 2010) , and elevated plasma concentrations are reported in Met carriers (Jung et al., 2012) . Despite the large sample size of this study (714 participants), a limitation is that women were not included because they were not part of infantry battalions at the time of assessment. Women show lower COMT activity than men, due to its estrogen-modulated downregulation (Chen et al., 2004; Hassan, Salama, Arafa, Hamada, & Al-Hendy, 2007; Tunbridge, 2010) . Furthermore, sex-dependent associations between COMT polymorphism and anxiety-related traits have been reported (Stein, Fallin, Schork, & Gelernter, 2005) . A previous large study showed no sex-dependent effect of COMT val158met polymorphism on impaired fear inhibition found in PTSD patients (Norrholm et al., 2013) . However, further investigation will be necessary to assess the potential Gene × Trauma interactions in women. 
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